Covestor Ltd Acquires 926 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Covestor Ltd grew its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 63.5% in the 3rd quarter, Holdings Channel.com reports. The firm owned 2,384 shares of the company’s stock after acquiring an additional 926 shares during the period. Covestor Ltd’s holdings in Inari Medical were worth $99,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in NARI. GAMMA Investing LLC raised its stake in Inari Medical by 164.7% during the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after buying an additional 438 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after purchasing an additional 435 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after purchasing an additional 522 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Inari Medical during the 2nd quarter valued at about $104,000. Finally, Quest Partners LLC increased its stake in Inari Medical by 31,257.1% during the 2nd quarter. Quest Partners LLC now owns 2,195 shares of the company’s stock valued at $106,000 after purchasing an additional 2,188 shares in the last quarter. 90.98% of the stock is owned by institutional investors.

Inari Medical Trading Down 3.8 %

Shares of NARI stock opened at $51.30 on Wednesday. The company has a 50 day simple moving average of $44.78 and a two-hundred day simple moving average of $46.81. The stock has a market cap of $3.00 billion, a P/E ratio of -38.00 and a beta of 0.96. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $67.13.

Insider Transactions at Inari Medical

In related news, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction on Monday, September 16th. The stock was sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the transaction, the director now directly owns 643,296 shares in the company, valued at approximately $29,482,255.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $45.83, for a total value of $1,833,200.00. Following the transaction, the director now owns 643,296 shares of the company’s stock, valued at $29,482,255.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Mitch C. Hill sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total value of $135,390.00. Following the transaction, the chief financial officer now owns 179,600 shares of the company’s stock, valued at approximately $8,105,348. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 126,000 shares of company stock worth $5,921,390 in the last three months. Corporate insiders own 10.60% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on NARI. Stifel Nicolaus assumed coverage on shares of Inari Medical in a report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Leerink Partners began coverage on Inari Medical in a research note on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 price target for the company. Piper Sandler increased their price objective on Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a research report on Tuesday, October 29th. Finally, Canaccord Genuity Group boosted their target price on Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a research report on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $58.89.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.